ClinicalTrials.gov
public full text
Public Domain
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
RATIONALE: Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab-labeled PET, may help doctors to plan a better treatment PURPOSE: This pilot trial is studying copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab-labeled positron emission tomography (PET) in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer Screening#890451
- Non-isotope Based Imaging Modalities vs Technetium-99m Single-Photon Emission Computed Tomography(99mTcSPECT)#870316
- HER2-positive Breast Cancer Project Initiated by Investigators#1009213
- Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014#1140049
- Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer#893265
Record · ID 907527
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive